Hugh M. Davis - Dec 2, 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
President and COO, Director
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Dec 2, 2025
Transactions value $
$0
Form type
4
Date filed
12/4/2025, 04:50 PM
Previous filing
Feb 4, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davis Hugh M. President and COO, Director C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE /s/ Matthew Rothman, Attorney-in-Fact 2025-12-04 0002045027

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +26.8K 26.8K Dec 2, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -26.8K -25% $0.00 80.3K Dec 2, 2025 Common Stock 26.8K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date.